NCT02288208View on ClinicalTrials.gov

Phase I Safety and Tolerability Study of Birinapant in Chronic Hepatitis B

PHASE1TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Hepatitis B
Interventions
DRUG

Antiviral Therapy (tenofovir or entecavir)

DRUG

Birinapant

DRUG

Placebo (for birinapant)

Trial Locations (3)

3004

Nucleus Network Limited / AMREP Precinct, Melbourne

5000

CMAX / Royal Adelaide Hospital, Adelaide

6009

Linear Clinical Research Ltd, Nedlands

Sponsors
All Listed Sponsors
lead

TetraLogic Pharmaceuticals

INDUSTRY

NCT02288208 - Phase I Safety and Tolerability Study of Birinapant in Chronic Hepatitis B | Biotech Hunter | Biotech Hunter